Papillary thyroid carcinoma with BRAFV600E mutation: Sonographic prediction

American Journal of Roentgenology

Volumn 194, Issue 5, 2010, Pages

  Hwang, Jiyoung ^a   Shin, Jung Hee ^a   Han, Boo Kyung ^a   Ko, Eun Young ^a   Kang, Seok Seon ^a   Kim, Jong Won ^a   Chung, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

BRAF mutation; Papillary thyroid carcinoma; Thyroid cancer; Ultrasonography

Indexed keywords

B RAF KINASE; B RAF KINASE V600E; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; ASPIRATION BIOPSY; CALCIFICATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DNA SEQUENCE; ECHOGRAPHY; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MUTATION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME; ULTRASOUND;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; KOREA; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; ULTRASONOGRAPHY;

EID: 77951950838     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3512     Document Type: Article

References (27)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295:2164-2167
2. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009; 18:784-791
3. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004; 14:1056-1060 (Pubitemid 40076130)
4. MacCorkle RA, Tan TH. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 2005; 43:451-461 (Pubitemid 41506881)
5. Torii S, Nakayama K, Yamamoto T, Nishida E. Regulatory mechanisms and function of ERK MAP kinases. J Biochem 2004; 136:557-561 (Pubitemid 40364176)
6. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28:742-762 (Pubitemid 350294294)
7. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003; 1653:25-40
8. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4:937-947 (Pubitemid 39626217)
9. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008; 8:83-95
10. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007; 148:936-941 (Pubitemid 46272777)
11. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTCRAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454-1457 (Pubitemid 36373628)
12. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45:818-821 (Pubitemid 39545368)
13. Kim SK, Kim DL, Han HS, et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008; 17:118-125
14. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245-262
15. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006; 13:455-464 (Pubitemid 43886668)
16. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90:6373-6379 (Pubitemid 41759286)
17. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88:5399-5404 (Pubitemid 37452745)
18. Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation - multicenter retrospective study. Radiology 2008; 247:762-770
19. Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR 2002; 178:687-691
20. Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 1995; 196:123-134
21. Fornage BD, Sneige N, Faroux MJ, Andry E. Sonographic appearance and ultrasound-guided fine-needle aspiration biopsy of breast carcinomas smaller than 1 cm3. J Ultrasound Med 1990; 9:559-568 (Pubitemid 20362828)
22. Das DK. Psammoma body: a product of dystrophic calcification or of a biologically active process that aims at limiting the growth and spread of tumor? Diagn Cytopathol 2009; 37:534-541
23. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88:4393-4397 (Pubitemid 37153748)
24. Lee JH, Lee ES, Kim YS, Won NH, Chae YS. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 2006; 38:201-204 (Pubitemid 43879713)
25. Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006; 244:799-804 (Pubitemid 44629955)
26. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110:38-46 (Pubitemid 46986416)
27. V600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93:3943-3949